Advances in Oligonucleotide Aptamers for NSCLC Targeting

Area of Science:

• Oncology
• Biotechnology
• Molecular Biology

Background:

• Non-small-cell lung cancer (NSCLC) is the most prevalent lung cancer globally, particularly in developed nations.
• Current NSCLC therapies often lead to patient resistance, relapse, and poor prognoses, especially when diagnosed at advanced stages.
• There is a critical need for novel diagnostic and therapeutic strategies to improve outcomes for NSCLC patients.

Purpose of the Study:

• To review the applications of SELEX technology and nucleic-acid aptamers in managing NSCLC.
• To highlight aptamers as potential tools for early NSCLC diagnosis and targeted treatment.
• To discuss how aptamers may overcome challenges like toxicity and resistance associated with existing therapies.

Main Methods:

• Systematic evolution of ligands by exponential enrichment (SELEX) is used for in vitro selection of aptamers.
• Aptamers are short single-stranded oligonucleotides designed to fold into specific 3D structures.
• These structures enable high-affinity binding to disease-associated proteins, serving as targeting ligands.

Main Results:

• Aptamers demonstrate potential as high-affinity ligands for disease-associated proteins relevant to NSCLC.
• SELEX technology facilitates the discovery of novel aptamers for diagnostic and therapeutic applications.
• Aptamer-based strategies show promise in addressing NSCLC early diagnosis and targeted therapy.

Conclusions:

• Nucleic-acid aptamers represent a promising class of molecules for NSCLC management.
• Aptamer technology offers a potential solution to overcome limitations of current NSCLC treatments, including toxicity and resistance.
• Further development of aptamer applications could significantly impact NSCLC diagnosis and therapy.